FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319812222> ?p ?o ?g. }

• W4319812222 abstract "Introduction. Piperacillin/tazobactam and carbapenems are important agents for the treatment of serious Gram-negative infections in hospitalized patients. Resistance to both agents is a significant concern in clinical isolates of Enterobacterales and Pseudomonas aeruginosa ; new agents with improved activity are needed. Gap Statement. Publication of current, region-specific data describing the in vitro activity of newer agents such as imipenem/relebactam (IMR) against piperacillin/tazobactam-resistant and carbapenem-resistant Enterobacterales and P. aeruginosa are needed to support their clinical use. Aim. To describe the in vitro activity of IMR against non- Morganellaceae Enterobacterales (NME) and P. aeruginosa isolated from bloodstream, intra-abdominal and urinary tract infection samples by hospital laboratories in Western Europe with a focus on the activity of IMR against piperacillin/tazobactam-resistant and meropenem-resistant isolates. Methodology. From 2018 to 2020, 29 hospital laboratories in six countries in Western Europe participated in the SMART global surveillance programme and contributed 9487 NME and 1004 P . aeruginosa isolates. MICs were determined by CLSI broth microdilution testing and interpreted by EUCAST (2021) breakpoints. β-Lactamase genes were identified in selected isolate subsets (2018–2020) and oprD sequenced in molecularly characterized P. aeruginosa (2020). Results. IMR (99.4 % susceptible), amikacin (98.0 %), meropenem (97.7 %) and imipenem (97.6 %) were the most active agents against NME; 83.1 % of NME were piperacillin/tazobactam-susceptible. Relebactam increased imipenem susceptibility of NME from Italy by 8.3 %, from Portugal by 2.9 %, and from France, Germany, Spain and the UK by <1 %. In total, 96.4 % of piperacillin/tazobactam-resistant ( n =1601) and 73.7 % of meropenem-resistant ( n =152) NME were IMR-susceptible. Also, 0.4 % of NME were MBL-positive, 0.9 % OXA-48-like-positive (MBL-negative) and 1.5 % KPC-positive (MBL-negative). Amikacin (95.4 % susceptible) and IMR (94.1 %) were the most active agents against P. aeruginosa ; 81.7 % of isolates were imipenem-susceptible and 79.6 % were piperacillin/tazobactam-susceptible. Relebactam increased susceptibility to imipenem by 12.5 % overall (range by country, 4.3–17.5 %); and by 30.7 % in piperacillin/tazobactam-resistant and 24.3 % in meropenem-resistant P. aeruginosa . In total, 1.6 % of P. aeruginosa isolates were MBL-positive. Seven of eight molecularly characterized IMR-resistant P. aeruginosa isolates from 2020 were oprD -deficient. Conclusion. IMR may be a potential treatment option for bloodstream, intra-abdominal and urinary tract infections caused by NME and P. aeruginosa in Western Europe, including infections caused by piperacillin/tazobactam-resistant and meropenem-resistant isolates." @default.
• W4319812222 created "2023-02-11" @default.
• W4319812222 creator A5017159626 @default.
• W4319812222 creator A5035614223 @default.
• W4319812222 creator A5037643218 @default.
• W4319812222 creator A5038009031 @default.
• W4319812222 creator A5042149117 @default.
• W4319812222 creator A5061522332 @default.
• W4319812222 creator A5063899317 @default.
• W4319812222 creator A5079571368 @default.
• W4319812222 creator A5089366807 @default.
• W4319812222 date "2023-02-10" @default.
• W4319812222 modified "2023-09-25" @default.
• W4319812222 title "In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018–2020" @default.
• W4319812222 cites W1618166169 @default.
• W4319812222 cites W2110880963 @default.
• W4319812222 cites W2190529098 @default.
• W4319812222 cites W2232017074 @default.
• W4319812222 cites W2392734635 @default.
• W4319812222 cites W2408072278 @default.
• W4319812222 cites W2423482339 @default.
• W4319812222 cites W2602667098 @default.
• W4319812222 cites W2807183168 @default.
• W4319812222 cites W2921754832 @default.
• W4319812222 cites W2955048139 @default.
• W4319812222 cites W2990287059 @default.
• W4319812222 cites W3006452222 @default.
• W4319812222 cites W3007020664 @default.
• W4319812222 cites W3048398081 @default.
• W4319812222 cites W3126580301 @default.
• W4319812222 cites W3158283085 @default.
• W4319812222 doi "https://doi.org/10.1099/jmm.0.001645" @default.
• W4319812222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36763081" @default.
• W4319812222 hasPublicationYear "2023" @default.
• W4319812222 type Work @default.
• W4319812222 citedByCount "0" @default.
• W4319812222 crossrefType "journal-article" @default.
• W4319812222 hasAuthorship W4319812222A5017159626 @default.
• W4319812222 hasAuthorship W4319812222A5035614223 @default.
• W4319812222 hasAuthorship W4319812222A5037643218 @default.
• W4319812222 hasAuthorship W4319812222A5038009031 @default.
• W4319812222 hasAuthorship W4319812222A5042149117 @default.
• W4319812222 hasAuthorship W4319812222A5061522332 @default.
• W4319812222 hasAuthorship W4319812222A5063899317 @default.
• W4319812222 hasAuthorship W4319812222A5079571368 @default.
• W4319812222 hasAuthorship W4319812222A5089366807 @default.
• W4319812222 hasConcept C176947019 @default.
• W4319812222 hasConcept C2777427914 @default.
• W4319812222 hasConcept C2777637488 @default.
• W4319812222 hasConcept C2777858937 @default.
• W4319812222 hasConcept C2778193466 @default.
• W4319812222 hasConcept C2778266534 @default.
• W4319812222 hasConcept C2779375183 @default.
• W4319812222 hasConcept C2779631663 @default.
• W4319812222 hasConcept C2780950330 @default.
• W4319812222 hasConcept C501593827 @default.
• W4319812222 hasConcept C523546767 @default.
• W4319812222 hasConcept C54355233 @default.
• W4319812222 hasConcept C71924100 @default.
• W4319812222 hasConcept C86803240 @default.
• W4319812222 hasConcept C89423630 @default.
• W4319812222 hasConcept C94665300 @default.
• W4319812222 hasConceptScore W4319812222C176947019 @default.
• W4319812222 hasConceptScore W4319812222C2777427914 @default.
• W4319812222 hasConceptScore W4319812222C2777637488 @default.
• W4319812222 hasConceptScore W4319812222C2777858937 @default.
• W4319812222 hasConceptScore W4319812222C2778193466 @default.
• W4319812222 hasConceptScore W4319812222C2778266534 @default.
• W4319812222 hasConceptScore W4319812222C2779375183 @default.
• W4319812222 hasConceptScore W4319812222C2779631663 @default.
• W4319812222 hasConceptScore W4319812222C2780950330 @default.
• W4319812222 hasConceptScore W4319812222C501593827 @default.
• W4319812222 hasConceptScore W4319812222C523546767 @default.
• W4319812222 hasConceptScore W4319812222C54355233 @default.
• W4319812222 hasConceptScore W4319812222C71924100 @default.
• W4319812222 hasConceptScore W4319812222C86803240 @default.
• W4319812222 hasConceptScore W4319812222C89423630 @default.
• W4319812222 hasConceptScore W4319812222C94665300 @default.
• W4319812222 hasIssue "2" @default.
• W4319812222 hasLocation W43198122221 @default.
• W4319812222 hasLocation W43198122222 @default.
• W4319812222 hasOpenAccess W4319812222 @default.
• W4319812222 hasPrimaryLocation W43198122221 @default.
• W4319812222 hasRelatedWork W2013041033 @default.
• W4319812222 hasRelatedWork W2023781323 @default.
• W4319812222 hasRelatedWork W2182425667 @default.
• W4319812222 hasRelatedWork W3008459943 @default.
• W4319812222 hasRelatedWork W4292689058 @default.
• W4319812222 hasRelatedWork W4317696124 @default.
• W4319812222 hasRelatedWork W4376226325 @default.
• W4319812222 hasRelatedWork W4381620931 @default.
• W4319812222 hasRelatedWork W2036997505 @default.
• W4319812222 hasRelatedWork W2188621193 @default.
• W4319812222 hasVolume "72" @default.
• W4319812222 isParatext "false" @default.
• W4319812222 isRetracted "false" @default.
• W4319812222 workType "article" @default.